Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD скачать в хорошем качестве

Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD

The FDA recently approved bimekizumab-bkzx (BIMZELX) for treating active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS) in adults. In this interview, Philip Mease, MD, discussed comparator studies between bimekizumab, ustekinumab, and risankizumab in patients with PsA. He emphasized the importance of conducting comparator analyses in the absence of head-to-head studies in a growing treatment landscape. “We always welcome companies mounting head-to-head studies, but we know that that takes quite a few patients to conduct those studies, and it's quite expensive,” he said. https://www.hcplive.com/view/comparin... #psoriaticarthritis #psa #rheumatology